Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRAME-001 Personalized Vaccine in Advanced NSCLC
NCT04998474Phase 2Unknown
- Sponsor
- Frame Cancer Therapeutics
- Start
- Jan 2022
- Primary completion
- Jan 2024
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of FRAME-001 in non-small cell lung cancer (NSCLC), sponsored by Frame Cancer Therapeutics. Status: unknown.
02
Drugs
FRAME-001
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04998474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04998474.